Although most basal cell carcinomas (BCCs) are easily treated with surgery, radiation, or medication, few options are available for locally advanced or metastatic disease. Recently, vismodegib, a small-molecule inhibitor of Smoothen (Smo), a protein activated in the Hedgehog signal transduction pathway, was approved for treating advanced, locally invasive, and metastatic BCC. More than 95% of BCCs have defects in the Hedgehog signal transduction pathway. Now, the safety and efficacy of sonidegib, a second Smo inhibitor, has been evaluated for locally advanced and metastatic BCC.
In this randomized, multicenter, double-blind, phase II trial, 79 patients received 200 mg of sonidegib daily and 151 received the 800-mg dose. Median follow-up was …
Reviewing Author
DisclosuresConsultant / Advisory board Astellas Pharmaceuticals
EquityVaxin
Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.
Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology
Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)
DisclosuresConsultant / Advisory board Astellas Pharmaceuticals
EquityVaxin
Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.
Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology
Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)